Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Cube who wrote (646)	3/9/2000 9:01:00 AM
From: Hockeyfan	Read Replies (2) \| Respond to of 1154

Biotech musical chairs.. As a current holder of Gene I have the following observations... These stocks are becoming obscenely overvalued. They are going up because their peers are going up which in turn spurs their peers on to higher highs. Investors appear to be assuming that each of these companies will be 100% successful in patenting, licensing and/or commercializing their technology. Only last summer mosts of these stocks were trading in the single digits. They were probably undervalued then, but what has changed? Have they all taken tremendous strides to prove, patent or develop their technology or are they just caught up in the frenzy to own screaming hot growth stocks in the next not sector? GENE, GERON, etc. got hammered yesterday. The highest flyers have the most to lose in a market correction. The winds of change blow and biotechs will eventually be out of favor again. Don't get stuck without a chair. Manage your money wisely. Good Luck.